Spots Global Cancer Trial Database for A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
Official Title: A Phase Ib, Open-label, Multicenter Study of Oral LXH254-centric Combinations in Adult Patients With Advanced or Metastatic KRAS or BRAF Mutant Non-Small Cell Lung Cancer or NRAS Mutant Melanoma
Study ID: NCT02974725
Study Description
Brief Summary: To characterize safety and tolerability and identify a recommended dose and regimen for the LXH254 in combination with LTT462 or trametinib or ribociclib.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of California San Diego ., San Diego, California, United States
UCSF Medical Center, San Francisco, California, United States
Massachusetts General Hospital SC, Boston, Massachusetts, United States
Memorial Sloan Kettering Cancer Ctr ., New York, New York, United States
Sarah Cannon Research Institute Tennessee Oncology, Nashville, Tennessee, United States
Uni of TX MD Anderson Cancer Cntr, Houston, Texas, United States
Novartis Investigative Site, Westmead, New South Wales, Australia
Novartis Investigative Site, Melbourne, Victoria, Australia
Novartis Investigative Site, Leuven, , Belgium
Novartis Investigative Site, Lyon, , France
Novartis Investigative Site, Paris 10, , France
Novartis Investigative Site, Villejuif, , France
Novartis Investigative Site, Dresden, , Germany
Novartis Investigative Site, Essen, , Germany
Novartis Investigative Site, Frankfurt, , Germany
Novartis Investigative Site, Koeln, , Germany
Novartis Investigative Site, Tel Aviv, , Israel
Novartis Investigative Site, Milano, MI, Italy
Novartis Investigative Site, Milano, MI, Italy
Novartis Investigative Site, Rozzano, MI, Italy
Novartis Investigative Site, Verona, VR, Italy
Novartis Investigative Site, Napoli, , Italy
Novartis Investigative Site, Seoul, , Korea, Republic of
Novartis Investigative Site, Seoul, , Korea, Republic of
Novartis Investigative Site, Warszawa, , Poland
Novartis Investigative Site, Sevilla, Andalucia, Spain
Novartis Investigative Site, Barcelona, Catalunya, Spain
Novartis Investigative Site, Barcelona, Catalunya, Spain
Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain
Novartis Investigative Site, Pamplona, Navarra, Spain
Novartis Investigative Site, Madrid, , Spain
Novartis Investigative Site, Stockholm, , Sweden
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
